Home › Trials › NCT03313271
Clinical trial Recruiting at 1 site Observational Ages 18 and up

Registry of lymphoma patients in China

Official title: China Lymphoma Patient Registry Study

Run by Peking University · NCT03313271 · Data updated 2026-11-12

This study is tracking over 500 lymphoma patients in China to see how the disease progresses and how different treatments work, with the hope of improving survival rates and quality of life.

More Lymphoma trials

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment5000 (estimated)
SponsorPeking University
Academic / other
Drugs / interventionschemotherapy
Locations1 site (Beijing, Beijing Municipality)
StatusRecruiting
StartedMay 17, 2017
Main results expectedMay 17, 2027
Study endsAugust 30, 2027
Registry record updatedOctober 18, 2017
Trial IDNCT03313271 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 18 and older who have been diagnosed with Hodgkin's or non-Hodgkin's lymphoma within the last six months.

Probably not a fit

Patients who do not have a confirmed diagnosis of lymphoma or are under 18 years old may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to establish a cohort of lymphoma patients in China to better understand disease progression, treatment, and prognosis. By following over 500 patients diagnosed with Hodgkin's or non-Hodgkin's lymphoma, the study seeks to collect comprehensive data on diagnosis, treatment, and outcomes. The goal is to bridge the gap in survival rates between China and the United States by providing essential information for clinical research and drug development. This long-term follow-up will help improve patient outcomes and quality of life.

Why it matters

Potential benefit: If successful, this study could lead to improved treatment strategies and better survival rates for lymphoma patients in China.

How similar studies have gone: Other countries, like South Korea and the United States, have successfully conducted similar observational cohort studies, indicating the potential for success in this approach in China.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* The disease was diagnosed by Hodgkin's or non Hodgkin's lymphoma
* 18 years of age or older at diagnosis
* The diagnosis was confirmed within 6 months before admission
* Informed consent was obtained

Exclusion Criteria:

* There are no special exclusion criteria in this study

Where it's running

  • Peking University Cancer Hospital
    Beijing, Beijing Municipality, China     Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Lymphoma 394Peking University 44
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.